- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07733778
Neuroendoscopic Lavage in the Management of Neonatal Intra-ventricular Hemorrhage
Role of Neuro-endoscopic Lavage in the Management of Neonatal Intra-ventricular Hemorrhage
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Neonatal intra-ventricular hemorrhage (IVH) is one of the most common and serious neurological complications affecting premature infants, particularly those born before 32 weeks of gestation and those with very low birth weight. Despite advances in neonatal intensive care, IVH remains a significant cause of mortality and long-term neurodevelopmental disability worldwide (1,2).
The pathogenesis of IVH is closely related to the fragility of the germinal matrix vasculature and the immaturity of cerebral auto-regulation in premature neonates. Fluctuations in cerebral blood flow may result in rupture of these fragile vessels, leading to hemorrhage that can extend into the ventricular system (2,3).
The severity of IVH is commonly classified according to the Papile grading system into four grades. Grades III and IV are associated with the highest rates of morbidity and mortality and carry a significant risk of developing post-hemorrhagic ventricular dilatation (PHVD) and post-hemorrhagic hydrocephalus (PHH) (1,4).
Post-hemorrhagic ventricular dilatation develops as a result of obstruction of cerebrospinal fluid (CSF) pathways by intra-ventricular blood clots and inflammatory debris. Furthermore, blood degradation products trigger inflammatory reactions that impair CSF circulation and absorption, leading to progressive ventricular enlargement and secondary brain injury (3,5).
Several treatment modalities have been proposed for the management of PHVD and PHH, including serial lumbar punctures, ventricular reservoir insertion, ventriculo-subgaleal shunting, external ventricular drainage (EVD), and ventriculo-peritoneal (VP) shunt placement. However, these methods primarily provide CSF diversion without directly removing intra-ventricular blood products that contribute to ongoing inflammation and ventricular dilatation (5,6).
Neuro-endoscopic lavage (NEL) has recently emerged as a promising minimally invasive technique for the treatment of severe neonatal IVH. The procedure involves endoscopic irrigation of the ventricular system with the aim of removing blood clots and inflammatory debris, restoring CSF pathways, and reducing ventricular enlargement. By addressing the underlying pathological substrate rather than merely diverting CSF, NEL may reduce shunt dependency and improve neurological outcomes (6,7).
Recent studies have reported encouraging results regarding the safety and efficacy of neuro-endoscopic lavage in neonates with severe IVH. These studies demonstrated reduction in ventricular size, lower rates of permanent VP shunt insertion, and favorable neurodevelopmental outcomes compared with conventional treatment methods (6,7). Nevertheless, current evidence remains limited, and further prospective studies are required to establish the exact role of neuro-endoscopic lavage in the management of neonatal intra-ventricular hemorrhage.
Therefore, this study aims to evaluate the role of neuro-endoscopic lavage in neonates with intra-ventricular hemorrhage and to assess its impact on ventricular dilatation, shunt dependency, complications, and clinical outcomes.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ahmed Aboelmagd, Assistant lecturer
- Número de teléfono: +20 01099474580
- Correo electrónico: ahmedaboelmagd@aun.edu.eg
Copia de seguridad de contactos de estudio
- Nombre: Mahmoud Gamal, Lecturer
- Número de teléfono: +20 01000630887
- Correo electrónico: Mahmoud-gamal@aun.edu.eg
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria
- Neonates aged 28 days or less at the time of presentation.
- Neonates diagnosed with severe IVH with ventricular dilatation (Grade III or IV on Papile classification).
- Written informed consent obtained from parents or legal guardians -
Exclusion Criteria:
- Grade I or Grade II intra-ventricular hemorrhage according to the Papile classification.
- Major congenital brain malformations, like Dandy-Walker malformation and Holoprosencephaly or severe congenital anomalies incompatible with life.
- Neonates with active central nervous system infection (meningitis or ventriculitis).
- Severe coagulopathy not correctable before surgery.
- Refusal of parental or legal guardian consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Neuro-endoscopic lavage in the management of neonatal intra-ventricular hemorrhage
Single arm
|
Neuro-endoscopic lavage for management of neonatal intra-ventricular hemorrhage using normal saline
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate of PHVD and permanent VP shunt insertion within the follow-up period after neuro-endoscopic lavage
Periodo de tiempo: 3 years
|
To evaluate the rate of post hemorrhagic ventricular dilatation and the need for permanent VP shunt after neuroendoscopic lavage for neonatal intra-ventricular hemorrhage
|
3 years
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978 Apr;92(4):529-34. doi: 10.1016/s0022-3476(78)80282-0.
- Ballabh P. Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatr Res. 2010 Jan;67(1):1-8. doi: 10.1203/PDR.0b013e3181c1b176.
- Levene MI, Wigglesworth JS, Dubowitz V. Cerebral structure and intraventricular haemorrhage in the neonate: a real-time ultrasound study. Arch Dis Child. 1981 Jun;56(6):416-24. doi: 10.1136/adc.56.6.416.
- Leijser LM, Miller SP, van Wezel-Meijler G, Brouwer AJ, Traubici J, van Haastert IC, Whyte HE, Groenendaal F, Kulkarni AV, Han KS, Woerdeman PA, Church PT, Kelly EN, van Straaten HLM, Ly LG, de Vries LS. Posthemorrhagic ventricular dilatation in preterm infants: When best to intervene? Neurology. 2018 Feb 20;90(8):e698-e706. doi: 10.1212/WNL.0000000000004984. Epub 2018 Jan 24.
- Schulz M, Buhrer C, Pohl-Schickinger A, Haberl H, Thomale UW. Neuroendoscopic lavage for the treatment of intraventricular hemorrhage and hydrocephalus in neonates. J Neurosurg Pediatr. 2014 Jun;13(6):626-35. doi: 10.3171/2014.2.PEDS13397. Epub 2014 Apr 4.
- Honeyman SI, Martin SC, Lawrence T, Calisto A, Jayamohan J, Magdum S. Neuroendoscopic lavage for the management of neonatal post-haemorrhagic hydrocephalus: A systematic review and meta-analysis. Childs Nerv Syst. 2025 Nov 28;41(1):385. doi: 10.1007/s00381-025-07023-9.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- Endoscopy in neonatal IVhge
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .